190 related articles for article (PubMed ID: 18413829)
1. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
Raje N; Woo SB; Hande K; Yap JT; Richardson PG; Vallet S; Treister N; Hideshima T; Sheehy N; Chhetri S; Connell B; Xie W; Tai YT; Szot-Barnes A; Tian M; Schlossman RL; Weller E; Munshi NC; Van Den Abbeele AD; Anderson KC
Clin Cancer Res; 2008 Apr; 14(8):2387-95. PubMed ID: 18413829
[TBL] [Abstract][Full Text] [Related]
2. Fluorodeoxyglucose positron emission tomography with computed tomography detects greater metabolic changes that are not represented by plain radiography for patients with osteonecrosis of the jaw.
Fleisher KE; Raad RA; Rakheja R; Gupta V; Chan KC; Friedman KP; Mourtzikos KA; Janal M; Glickman RS
J Oral Maxillofac Surg; 2014 Oct; 72(10):1957-65. PubMed ID: 25053572
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
[TBL] [Abstract][Full Text] [Related]
4. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
7. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
Musolino C; Oteri G; Allegra A; Mania M; D'Ascola A; Avenoso A; Innao V; Allegra AG; Campo S
Ann Hematol; 2018 Jul; 97(7):1259-1269. PubMed ID: 29546453
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
Van Poznak C; Estilo C
Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
[TBL] [Abstract][Full Text] [Related]
9. Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Gabbert TI; Hoffmeister B; Felsenberg D
J Cancer Res Clin Oncol; 2015 Apr; 141(4):749-58. PubMed ID: 25319961
[TBL] [Abstract][Full Text] [Related]
10. Osteonecrosis of the jaw in patients on bisphosphonate treatment. review of literature with contribution of a case of multiple myeloma.
Goranova-Marinova VS; Pechalova-Petrova PF; Goranov SG
Folia Med (Plovdiv); 2009; 51(4):53-7. PubMed ID: 20232660
[TBL] [Abstract][Full Text] [Related]
11. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
12. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
Delibasi T; Altundag K; Kanlioglu Y
J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
[No Abstract] [Full Text] [Related]
13. CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.
Lee CY; Suzuki JB
Implant Dent; 2010 Feb; 19(1):29-38. PubMed ID: 20147814
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis.
Ortega C; Montemurro F; Faggiuolo R; Vormola R; Nanni D; Goia F; Gilardino MO; Aglietta M
Acta Oncol; 2007; 46(5):664-8. PubMed ID: 17562443
[TBL] [Abstract][Full Text] [Related]
15. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
[TBL] [Abstract][Full Text] [Related]
16. Intravenous bisphosphonate-associated osteonecrosis of the jaw.
Statz TA; Guthmiller JM; Humbert LA; Johnson GK
J Periodontol; 2007 Nov; 78(11):2203-8. PubMed ID: 17970689
[TBL] [Abstract][Full Text] [Related]
17. Imaging findings in bisphosphonate-related osteonecrosis of jaws.
Arce K; Assael LA; Weissman JL; Markiewicz MR
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):75-84. PubMed ID: 19371818
[TBL] [Abstract][Full Text] [Related]
18. Positron-emission tomography imaging in the diagnosis of bisphosphonate-related osteonecrosis of the jaw.
Wilde F; Steinhoff K; Frerich B; Schulz T; Winter K; Hemprich A; Sabri O; Kluge R
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Mar; 107(3):412-9. PubMed ID: 19121962
[TBL] [Abstract][Full Text] [Related]
19. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
20. [Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
Calvo-Villas JM; Tapia Torres M; Govantes Rodríguez J; Carreter de Granda E; Sicilia Guillén F
Med Clin (Barc); 2006 Oct; 127(15):576-9. PubMed ID: 17153267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
